Phase 2 Melanoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are able to give informed consent and sign the required study forms
• People who are 18 years of age or older
• People whose cancer-related physical functioning falls within a certain range, meaning they are either fully active, have some limitations but can care for themselves, or are up and about more than half of waking hours (confirm with trial site)
• People who have been confirmed by tissue testing to have stage 4 (metastatic) cancer that has spread to other parts of the body
• People who have a confirmed RAS gene mutation (specifically KRAS, HRAS, or NRAS) identified by a tumour tissue test within the last 5 years
• People who have already received more than 2 different standard cancer drug treatments
• People whose cancer has been shown to be growing or spreading based on standard imaging measurement criteria (RECIST version 1.1)
• People whose blood counts, kidney function, and liver function meet certain minimum levels — including adequate white blood cells, platelets, red blood cells, kidney filtering ability, and liver markers (confirm specific values with trial site)
• Women who could become pregnant and who agree to either abstain from heterosexual intercourse or use at least two highly effective forms of contraception during treatment
• People who have brain metastases (cancer that has spread to the brain) that are not causing symptoms, where the treating doctor has determined that targeted local treatment is not needed

Who may not be able to join:

• People who are over 85 years of age
• People who currently have an active infection, whether recent or ongoing
• People with significantly reduced kidney or liver function, or a heart pumping function below 45%
• People with a known history of hepatitis B or C (due to potential effects of one of the study drugs, leflunomide, on the liver)
• People who have had an allergic reaction to leflunomide, teriflunomide, or chemically similar compounds used in the treatment combination
• People with serious uncontrolled health conditions, such as active infection, heart failure, unstable chest pain, heart rhythm problems, or mental health or social circumstances that could affect participation in the study
• People who are pregnant or breastfeeding, due to potential risks from the study treatments
• People with a history of certain eye conditions, such as retinal tears, bleeding in the eye, retinal vein blockage, or certain other retinal diseases — or people with current risk factors such as uncontrolled glaucoma or a history of blood-thickening conditions (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.